"We need to find and treat people much earlier."
With grim prognoses and very limited treatments for Alzheimer’s
disease, early detection isn’t particularly advantageous. But that may be
changing—fast. One of the hottest areas of Alzheimer's research involves
treating people in the very earliest stages of the disease with drugs that
decrease the production of amyloid beta (proteins that bunch together to form
damaging plaques in the brain). Experts believe that people begin to develop
amyloid plaques in their brains at least 10 years before they develop any
obvious symptoms of dementia.
Reisa Sperling, MD, director of the Center for Alzheimer Research and Treatment at Brigham and Women’s Hospital in Boston is leading a new clinical trial, called theA4 study, which will evaluate patients with evidence of Alzheimer’s damage in the brain but who still have normal thinking and memory function. The trial will randomly assign groups to receive medication, and researchers will determine over three years whether the drugs affected the patients’ memory or levels of amyloid. “When a person already has a lot of memory trouble, they already have significant neuron loss,” says Dr. Sperling. “We need to find and treat people much earlier.” Here's what to watch for.
Reisa Sperling, MD, director of the Center for Alzheimer Research and Treatment at Brigham and Women’s Hospital in Boston is leading a new clinical trial, called theA4 study, which will evaluate patients with evidence of Alzheimer’s damage in the brain but who still have normal thinking and memory function. The trial will randomly assign groups to receive medication, and researchers will determine over three years whether the drugs affected the patients’ memory or levels of amyloid. “When a person already has a lot of memory trouble, they already have significant neuron loss,” says Dr. Sperling. “We need to find and treat people much earlier.” Here's what to watch for.